ATE545866T1 - Liganden von g-protein-gekoppelten rezeptoren und verfahren - Google Patents

Liganden von g-protein-gekoppelten rezeptoren und verfahren

Info

Publication number
ATE545866T1
ATE545866T1 AT03718335T AT03718335T ATE545866T1 AT E545866 T1 ATE545866 T1 AT E545866T1 AT 03718335 T AT03718335 T AT 03718335T AT 03718335 T AT03718335 T AT 03718335T AT E545866 T1 ATE545866 T1 AT E545866T1
Authority
AT
Austria
Prior art keywords
methods
protein
ligands
coupled receptors
relates
Prior art date
Application number
AT03718335T
Other languages
German (de)
English (en)
Inventor
Ying Jiang
Fang Zhang
Nicholas Murgolo
Lin Luo
Jason Simon
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE545866T1 publication Critical patent/ATE545866T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
AT03718335T 2002-04-12 2003-04-10 Liganden von g-protein-gekoppelten rezeptoren und verfahren ATE545866T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37264002P 2002-04-12 2002-04-12
PCT/US2003/011159 WO2003087134A2 (en) 2002-04-12 2003-04-10 G-protein coupled receptor ligands and methods

Publications (1)

Publication Number Publication Date
ATE545866T1 true ATE545866T1 (de) 2012-03-15

Family

ID=29250884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718335T ATE545866T1 (de) 2002-04-12 2003-04-10 Liganden von g-protein-gekoppelten rezeptoren und verfahren

Country Status (9)

Country Link
US (3) US7338772B2 (enExample)
EP (1) EP1532446B1 (enExample)
JP (4) JP4594623B2 (enExample)
CN (1) CN1324047C (enExample)
AT (1) ATE545866T1 (enExample)
AU (1) AU2003221878A1 (enExample)
CA (1) CA2481508A1 (enExample)
MX (1) MXPA04009959A (enExample)
WO (1) WO2003087134A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4594623B2 (ja) * 2002-04-12 2010-12-08 シェーリング コーポレイション Ｇタンパク質共役レセプターリガンドおよび方法
WO2006039256A1 (en) * 2004-09-29 2006-04-13 Glaxo Group Limited Use of gpr103 agonists for modulating feeding behaviour
WO2009043524A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of a peptide as therapeutic agent
JP5313068B2 (ja) * 2009-03-09 2013-10-09 富士フイルム株式会社 側視内視鏡装置
CA2963579C (en) * 2014-10-14 2023-10-31 Universite De Montreal Biosensor based on g-beta-gamma-interacting proteins to monitor g-protein activation
JP6405352B2 (ja) * 2016-09-16 2018-10-17 株式会社Ｓｕｂａｒｕ 直噴内燃機関のピストン

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CN1167490A (zh) * 1994-11-10 1997-12-10 人体基因组科学有限公司 人司登尼亚钙蛋白-α
WO1997037967A1 (en) 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
WO2000011015A1 (en) 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
KR20010080882A (ko) 1998-10-13 2001-08-25 리처드 피. 버군 쥬니어 구성적으로 활성화된 비내생성 인간 ｇ 단백질 결합형수용체
PT1133559E (pt) 1998-11-20 2005-10-31 Arena Pharm Inc Receptor acoplato a proteina g orfao humano, rup3
WO2000031256A1 (fr) 1998-11-20 2000-06-02 Chugai Research Institute For Molecular Medicine, Inc. Nouveau gene codant une proteine membranaire specifique au cerveau
CN1550235A (zh) 1999-04-29 2004-12-01 ŵ��Ų�ڿ˹�˾ 结合肝素的拮抗剂在缓激肽释放的抑制中的应用
EP1189944A4 (en) 1999-06-21 2002-09-11 Smithkline Beecham Corp AXOR16, R CEPTEUR COUPL UNE PROT INE G
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
WO2001016316A1 (fr) 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Proteine recepteur couplee a une proteine g et adn correspondant
AU7645700A (en) * 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
WO2001048189A1 (fr) 1999-12-28 2001-07-05 Helix Research Institute Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers
AU2001271838A1 (en) * 2000-07-06 2002-01-21 Bayer Corporation Human neuropeptide y-like g protein-coupled receptor
WO2003020932A1 (en) * 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. Novel secretory proteins and dna thereof
JP4594623B2 (ja) * 2002-04-12 2010-12-08 シェーリング コーポレイション Ｇタンパク質共役レセプターリガンドおよび方法

Also Published As

Publication number Publication date
CN1324047C (zh) 2007-07-04
CA2481508A1 (en) 2003-10-23
EP1532446A4 (en) 2006-06-07
JP4594623B2 (ja) 2010-12-08
JP2010279373A (ja) 2010-12-16
US20030223992A1 (en) 2003-12-04
US7338772B2 (en) 2008-03-04
AU2003221878A1 (en) 2003-10-27
JP2010252805A (ja) 2010-11-11
WO2003087134A3 (en) 2005-03-24
AU2003221878A8 (en) 2003-10-27
JP2006254916A (ja) 2006-09-28
US8133980B2 (en) 2012-03-13
JP2005528894A (ja) 2005-09-29
JP5284313B2 (ja) 2013-09-11
US7807390B2 (en) 2010-10-05
US20080138348A1 (en) 2008-06-12
MXPA04009959A (es) 2004-12-13
WO2003087134A2 (en) 2003-10-23
EP1532446B1 (en) 2012-02-15
EP1532446A2 (en) 2005-05-25
CN1659438A (zh) 2005-08-24
US20110020354A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
DE60328870D1 (de) Verfahren zur modulierung von cd200-rezeptoren
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
BR0314192A (pt) Antagonistas de receptores de mglu para tratamento de distúrbios associados com receptores de mglu incluindo vìcio e depressão
BR9710988A (pt) Método e compostos moduladores receptores de androgênio
BR0315167A (pt) Métodos para tratar a da dor administrando-se um antagonista do fator de crescimento de nervos e um analgésico opióide e composições contendo os mesmos
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE315230T1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
BR0205829A (pt) Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
DE60207254D1 (de) Natürlicher ligand von gpcr chemr23 und dessen verwendung
ATE400653T1 (de) Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
MY150210A (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
ATE545866T1 (de) Liganden von g-protein-gekoppelten rezeptoren und verfahren
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
WO2003088904A3 (en) Screening and therapeutic methods for treating circadian rhythm disorders
HRP20041014B1 (hr) Novi spojevi kao modulatori opioidnog receptora
NO20065768L (no) Karbonsamid-opioidforbindelser
WO2002018941A3 (en) Screen for glutamate reuptake inhibitors, stimulators, and modulators
ATE504600T1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
EA200700951A1 (ru) БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG
AU2003211040A8 (en) The eaat2 promoter and uses thereof
ATE230263T1 (de) At1 rezeptor antagonist zur anregung von apoptosis
WO2005038006A3 (en) Chimeric metabotropic glutamate receptors and uses thereof
ATE422506T1 (de) Verwendung von löslichem t-cadherin zur behandlung von stoffwechselkrankheiten
DE60004473D1 (de) Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen